Yabing Cao

1.7k total citations
52 papers, 811 citations indexed

About

Yabing Cao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yabing Cao has authored 52 papers receiving a total of 811 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Yabing Cao's work include Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). Yabing Cao is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). Yabing Cao collaborates with scholars based in China, Macao and United States. Yabing Cao's co-authors include Tongyu Lin, Sheng Ye, Wei Wang, Haoran Li, Jun Zhu, Xiangyuan Wu, Xueying Li, Hongyu Zhang, He Huang and Yingcheng Lin and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Yabing Cao

46 papers receiving 800 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yabing Cao China 15 350 191 189 182 144 52 811
Yufan Cheng China 16 385 1.1× 190 1.0× 120 0.6× 102 0.6× 108 0.8× 51 949
Lara Alessandrini Italy 17 284 0.8× 217 1.1× 92 0.5× 33 0.2× 82 0.6× 69 827
Tong-Yu Lin China 22 586 1.7× 444 2.3× 177 0.9× 63 0.3× 237 1.6× 47 1.3k
Li‐Jian Liang China 17 474 1.4× 141 0.7× 292 1.5× 535 2.9× 63 0.4× 33 986
Leonard Christopher Schmeel Germany 16 237 0.7× 130 0.7× 140 0.7× 34 0.2× 154 1.1× 67 816
Chao-Jung Tsao Taiwan 11 195 0.6× 153 0.8× 307 1.6× 411 2.3× 34 0.2× 22 783
B. Vasseur France 12 522 1.5× 149 0.8× 112 0.6× 32 0.2× 129 0.9× 34 887
Veena Shah United States 13 186 0.5× 297 1.6× 75 0.4× 45 0.2× 134 0.9× 25 670
Paola Simona Ravenda Italy 12 324 0.9× 118 0.6× 93 0.5× 67 0.4× 275 1.9× 16 737

Countries citing papers authored by Yabing Cao

Since Specialization
Citations

This map shows the geographic impact of Yabing Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yabing Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yabing Cao more than expected).

Fields of papers citing papers by Yabing Cao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yabing Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yabing Cao. The network helps show where Yabing Cao may publish in the future.

Co-authorship network of co-authors of Yabing Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Yabing Cao. A scholar is included among the top collaborators of Yabing Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yabing Cao. Yabing Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Jianlei, Jiang Yin, Weina Fan, et al.. (2025). SPP1+ macrophages polarized by lactate confer the progression of hypoxic adaptive tumor cells in brain. Neuro-Oncology. 28(1). 70–85. 1 indexed citations
2.
Dun, S.L., Qifeng Zhou, Wen Xia, et al.. (2025). Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer. npj Breast Cancer. 11(1). 123–123.
3.
4.
Guo, De‐Zhen, Shiyu Zhang, Jiayan Yan, et al.. (2023). Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. Frontiers in Oncology. 13. 1109742–1109742. 6 indexed citations
5.
Cai, Jun, Yabing Cao, & Elaine Lai‐Han Leung. (2023). Detection of Single Non-small Cell Lung Cancer Cell Multidrug Resistance with Single-Cell Bioanalyzer. Methods in molecular biology. 2689. 1–11. 1 indexed citations
6.
Guo, De‐Zhen, Shiyu Zhang, Jiayan Yan, et al.. (2023). Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy. Frontiers in Immunology. 14. 1141199–1141199. 5 indexed citations
7.
Leung, Elaine Lai‐Han, Xing‐Xing Fan, Jumin Huang, et al.. (2022). Holistic immunomodulation for small cell lung cancer. Seminars in Cancer Biology. 88. 96–105. 6 indexed citations
8.
Xu, Xin, Ao Huang, De‐Zhen Guo, et al.. (2022). Integration of Inflammation-Immune Factors to Build Prognostic Model Predictive of Prognosis and Minimal Residual Disease for Hepatocellular Carcinoma. Frontiers in Oncology. 12. 893268–893268. 1 indexed citations
9.
Huang, Jumin, Zebo Jiang, Yuwei Wang, et al.. (2020). Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy. Current Opinion in Pharmacology. 54. 1–10. 45 indexed citations
10.
Cao, Yabing, et al.. (2019). Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. PLoS ONE. 14(8). e0221575–e0221575. 15 indexed citations
11.
Cao, Yabing, et al.. (2019). Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma. BMC Cancer. 19(1). 1022–1022. 15 indexed citations
12.
Cao, Yabing, et al.. (2017). Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. Annals of Oncology. 28. x129–x129. 1 indexed citations
13.
14.
Fu, Yi‐Peng, Yong Yi, Xiaoyan Cai, et al.. (2016). Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. British Journal of Cancer. 114(7). 767–776. 63 indexed citations
15.
Cao, Yabing, et al.. (2014). Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients. PLoS ONE. 9(12). e114008–e114008. 14 indexed citations
16.
17.
Zeng, Liang, Lihua Gao, Deyun Feng, et al.. (2012). Detection of STAT2 in early stage of cervical premalignancy and in cervical cancer. Asian Pacific Journal of Tropical Medicine. 5(9). 738–742. 13 indexed citations
18.
Jin, Ying, Yan Cai, Yabing Cao, et al.. (2011). To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area. European Journal of Cancer. 48(6). 882–888. 57 indexed citations
19.
Guo, Chengcheng, Yabing Cao, Jian Xiao, et al.. (2009). Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin’s lymphoma: single center, 15-year experience. International Journal of Hematology. 91(1). 78–86. 17 indexed citations
20.
Cao, Yabing, et al.. (2007). [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].. PubMed. 36(10). 654–9. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yufan Cheng Breakdown of academic impact, for papers by Lara Alessandrini Breakdown of academic impact, for papers by Tong-Yu Lin Breakdown of academic impact, for papers by Li‐Jian Liang Breakdown of academic impact, for papers by Leonard Christopher Schmeel Breakdown of academic impact, for papers by Chao-Jung Tsao Breakdown of academic impact, for papers by B. Vasseur Breakdown of academic impact, for papers by Veena Shah Breakdown of academic impact, for papers by Paola Simona Ravenda
Rankless by CCL
2026